NCT07691762Not yet recruitingPhase 3
A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma
A Phase III, Randomized, Double-blind, Multicenter Study of SHR-8068 and Adebrelimab Plus Bevacizumab in Combination With TACE in Participants With Incurable Hepatocellular Carcinoma
Source: ClinicalTrials.gov · Last updated 29 Oct 2026
Brief summary (registry, in English)
This is a multicenter, Phase 3 clinical trial to evaluate the efficacy and safety of SHR-8068, Adebrelimab, and Bevacizumab and TACE versus Placebo with TACE in incurable hepatocellular carcinoma. Participants will continue treatment until disease progresses, intolerable toxicity, withdrawal of informed consent, loss of follow-up, death, or other circumstances that require termination of treatment, whichever occurs first.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 690 (estimated)
- First submitted
- 2 Jul 2026
- Start date
- Nov 2026
- Primary completion date
- Sept 2031
- Lead sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07691762
What you commit to
- Study type: Interventional · Phase 3
- Planned participants: 690
- From Nov 2026 to the primary completion date, Sept 2031
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior esophageal and/or gastric varices bleeding within 6 months prior to initiation of study treatment;
Other illness
- Fibrolamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma or mixed cholangiocarcinoma / hepatocellular carcinoma; Participants with other malignancies currently or within the past 5 years;
- Participants with any active, known or suspected autoimmune disorder;
- Participants with hypertension which cannot be well controlled by antihypertensives;
- Uncontrolled cardiac diseases or symptoms;
- History of gastrointestinal perforation and/or fistula;
Other
- Participants with hepatic encephalopathy;
- Participants with other potential factors that may affect the study results.
Who the study is looking for
- Age 18-75 years old, male or female;
- Diagnosis confirmed HCC by pathologically or clinically;
- At least one measurable lesion;
- Child-Pugh liver function grade A;
- ECOG-PS score: 0 or 1;
- Eligible for TACE treatment as assessed by the investigator;
- Participants with HBV or HCV infection must be on and remain on standard antiviral therapy throughout the study period;
- Consent to contraception.
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Zhongda Hospital Southeast University Coordinator of this site? Confirm its status | Nanjing | China | Unknown status |
| Zhongshan Hospital,Fudan University Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.